Metraipolis › archive › dc_896a01e9df7b

Antibody-drug conjugates in gynecologic malignancies: breakthroughs, challenges, and future directions — Europe PMC PMID:42375351

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42375351
DOI
10.3389/fimmu.2026.1831465
License (as archived)
solo-consultazione
Archived
2026-10-31T11:19:22.741Z
SHA-256 of the archived text
4bb9d755de19547e3a8efd823367abd1e4314615b2df54aa6f7157649bd20164
Stable URL of this page
https://metraipolis.com/documento/dc_896a01e9df7b

How to cite

Antibody-drug conjugates in gynecologic malignancies: breakthroughs, challenges, and future directions — Europe PMC PMID:42375351 — Europe PMC (en), https://europepmc.org/article/MED/42375351 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_896a01e9df7b (Metraipolis archive dc_896a01e9df7b, sha256 4bb9d755de19547e3a8efd823367abd1e4314615b2df54aa6f7157649bd20164)
BibTeX
@misc{dc896a01e9df7b,
  title = {Antibody-drug conjugates in gynecologic malignancies: breakthroughs, challenges, and future directions — Europe PMC PMID:42375351},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42375351},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_896a01e9df7b; sha256 4bb9d755de19547e3a8efd823367abd1e4314615b2df54aa6f7157649bd20164},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42375351. Agents can read the archived copy with the MCP tool read_document.